Source comparison
Why the DAC vs No DAC Distinction Is Non-Negotiable
The presence or absence of Drug Affinity Complex (DAC). A lysine linker that binds the peptide to serum albumin. Fundamentally alters pharmacokinetics. CJC-1295 WITH DAC remains active for 6–8 days, producing sustained elevation of baseline growth hormone rath
This comparison does not assign a generated winner or score.
- The presence or absence of Drug Affinity Complex (DAC). A lysine linker that binds the peptide to serum albumin. Fundamentally alters pharmacokinetics. CJC-1295 WITH DAC remains active for 6–8 days, producing sustained elevation of baseline growth hormone rather than mimicking natural pulsatile release. CJC-1295 No DAC (or Mod GRF) clears the system within 2–3 hours, creating a sharp GH pulse that subsides before the next scheduled dose. For protocols designed to replicate physiological GH secretion patterns. The standard approach in metabolic and body composition research. The short-acting version is required. Using the DAC version in a pulsatile protocol design is a category error that cannot be corrected post-administration.
- Here's what our experience shows: research teams ordering "CJC-1295" without specifying DAC status receive the long-acting version roughly 40% of the time, purely because some suppliers default to the albumin-bound form. The downstream consequence is data incompatibility. Sustained GH elevation affects IGF-1 feedback loops, insulin sensitivity, and lipolytic signaling differently than pulsatile release. A study designed around three-times-daily pulsatile dosing will produce unusable results if the compound administered was the week-long DAC version. We mean this: verifying "No DAC" or "Mod GRF" explicitly in the order specification is the only reliable safeguard. The two compounds are not interchangeable.